☆ 4.4 Article

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England

NEUROLOGY AND THERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening

Tamara Dangouloff et al.

Summary: This study aims to compare the societal financial costs and quality of life (QoL) between untreated patients with spinal muscular atrophy (SMA) and treated patients identified by symptoms or early testing. The results show that the total costs are lower for untreated patients, but lower for patients identified by early testing. Early patient identification and treatment can reduce the overall societal costs of SMA.

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme

Arlene M. D'Silva et al.

Summary: This study dynamically designed, evaluated, and implemented the components of an Australian newborn bloodspot screening (NBS) pilot programme for spinal muscular atrophy (SMA). Results showed that the NBS pilot test protocol had high sensitivity, specificity, and positive predictive value for identifying SMA in newborn infants. The study highlights the importance of NBS for early detection and prediction of SMA in infants.

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2) : a phase 3, double-blind, randomised, placebo-controlled trial

Eugenio Mercuri et al.

Summary: Risdiplam has shown significant improvement in motor function compared to placebo in patients with type 2 or non-ambulant type 3 spinal muscular atrophy. Motor function generally improved in younger patients and stabilized in older patients.

LANCET NEUROLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

Kevin A. Strauss et al.

Summary: Onasemnogene abeparvovec was effective and well tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention.

NATURE MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

Kevin A. Strauss et al.

Summary: SPR1NT (NCT03505099) is a Phase III study investigating the efficacy and safety of onasemnogene abeparvovec in presymptomatic children with biallelic SMN1 mutations. The results showed that all 14 infants enrolled in the study were able to sit independently for at least 30 seconds within 18 months and none required permanent ventilation. The treatment was well tolerated and effective for children expected to develop SMA type 1.

NATURE MEDICINE (2022)

添加到收藏夹

Article Economics

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands

Rimma Velikanova et al.

Summary: In this study conducted in the Netherlands, including spinal muscular atrophy (SMA) in the newborn screening program was found to improve health outcomes, reduce healthcare costs, and maximize survival through early detection and treatment.

VALUE IN HEALTH (2022)

添加到收藏夹

Article Clinical Neurology

Newborn Screening for SMA - Can a Wait-and-See Strategy be Responsibly Justified in Patients With Four SMN2 Copies?

Astrid Blaschek et al.

Summary: Early treatment is crucial for preventing disease progression in SMA patients with four copies of SMN2.

JOURNAL OF NEUROMUSCULAR DISEASES (2022)

添加到收藏夹

Article Clinical Neurology

Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia

Tianjiao Wang et al.

Summary: This study aimed to analyze the cost-effectiveness of AVXS-101 and nusinersen for SMA treatment, and concluded that both treatments are not cost-effective.

JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Meeting Abstract Clinical Neurology

Cost-effectiveness of spinal muscular atrophy newborn screening in Belgium

T. Dangouloff et al.

NEUROMUSCULAR DISORDERS (2022)

添加到收藏夹

Article Genetics & Heredity

Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency

Sophy T. F. Shih et al.

Summary: This study aimed to investigate the costs and outcomes associated with the introduction of universal newborn screening (NBS) for severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA). The findings suggested that screening every newborn and providing early treatment could result in cost savings and improved life quality.

INTERNATIONAL JOURNAL OF NEONATAL SCREENING (2022)

添加到收藏夹

Article Clinical Neurology

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Eugenio Mercuri et al.

Summary: The STR1VE-EU study evaluated the safety and efficacy of onasemnogene abeparvovec gene replacement therapy in infants with spinal muscular atrophy type 1, showing effectiveness in symptomatic patients and a favorable benefit-risk profile for this patient population. Further long-term safety studies are needed.

LANCET NEUROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Risdiplam in Type 1 Spinal Muscular Atrophy

Giovanni Baranello et al.

Summary: In a study involving 21 infants with type 1 spinal muscular atrophy, treatment with oral risdiplam resulted in increased levels of functional SMN protein in the blood. Infants in the high-dose group were more likely to sit without support for at least 5 seconds, and the higher dose of risdiplam was selected for the second part of the study.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium

Francois Boemer et al.

Summary: Three new therapies for SMA have been approved by FDA and EMA since 2016, with emphasis on early administration before symptoms. A pilot program in Belgium successfully transitioned into an official neonatal screening program, providing valuable lessons for newborn screening.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Clinical Neurology

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

John W. Day et al.

Summary: The study evaluated the safety and efficacy of onasemnogene abeparvovec gene therapy in symptomatic patients with infantile-onset spinal muscular atrophy. Results showed that patients achieved independent sitting and survival rates without permanent ventilation at certain time points, with a favorable benefit-risk profile supporting the use of onasemnogene abeparvovec for treatment of this condition.

LANCET NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go

Tamara Dangouloff et al.

Summary: The study provides a global overview on the current situation and perspectives on SMA NBS, pointing out the differences in funding, screening methods, organization, and consent process between countries. Experts expressed a strong need for the implementation of SMA NBS to improve patient care.

NEUROMUSCULAR DISORDERS (2021)

添加到收藏夹

Article Genetics & Heredity

Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years

Katharina Vill et al.

Summary: The study assessed the impact of genetic newborn screening for spinal muscular atrophy (SMA) on disease outcomes, showing that early diagnosis and treatment of SMA are crucial in preventing major disability, with newborn screening results consistent with known incidence in Germany. Timely SMA-specific treatment significantly improves neurodevelopmental outcomes.

ORPHANET JOURNAL OF RARE DISEASES (2021)

添加到收藏夹

Article Clinical Neurology

Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis

Sophy T. F. Shih et al.

Summary: Newborn screening and early gene therapy significantly improves the quality and length of life for infants with spinal muscular atrophy (SMA), compared to late treatment with nusinersen. The cost-effectiveness analysis suggests that early gene therapy is dominant over late nusinersen treatment, with substantial QALY gains and cost savings per infant screened. Probability sensitivity analyses also support the value of newborn screening and gene therapy in improving outcomes for SMA infants.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

添加到收藏夹

Article Medicine, General & Internal

Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

Basil T. Darras et al.

Summary: In this study involving infants with type 1 SMA, treatment with risdiplam resulted in higher percentages of infants who achieved motor milestones and showed improvements in motor function compared to historical controls. Longer and larger trials are needed to confirm the long-term safety and efficacy of risdiplam in infants with type 1 SMA.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Genetics & Heredity

Landscape of Spinal Muscular Atrophy Newborn Screening in the United States: 2018-2021

Kshea Hale et al.

Summary: Newborn screening programs in the United States identify newborns at risk for genetic disorders, with 34 state programs fully implementing Spinal Muscular Atrophy (SMA) screening as of June 2021, and at least 8 others pursuing implementation. The Health and Human Services Advisory Committee on Heritable Disorders in Newborns and Children recommends disorders to screen for state programs, including SMA added to the screening panel in 2018.

INTERNATIONAL JOURNAL OF NEONATAL SCREENING (2021)

添加到收藏夹

Article Genetics & Heredity

The implementation of newborn screening for spinal muscular atrophy: the Australian experience

Didu S. T. Kariyawasam et al.

GENETICS IN MEDICINE (2020)

添加到收藏夹

Article Clinical Neurology

244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands

Tamara Dangouloff et al.

NEUROMUSCULAR DISORDERS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

New treatments in spinal muscular atrophy: an overview of currently available data

Sithara Ramdas et al.

EXPERT OPINION ON PHARMACOTHERAPY (2020)

添加到收藏夹

Article Genetics & Heredity

Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy

Denise M. Kay et al.

GENETICS IN MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?

Maria Carmela Pera et al.

PLOS ONE (2020)

添加到收藏夹

Article Clinical Neurology

AAN position statement: Ethical issues in clinical research in neurology

Benjamin Tolchin et al.

NEUROLOGY (2020)

添加到收藏夹

Article Pediatrics

Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy

Ali Jalali et al.

JOURNAL OF PEDIATRICS (2020)

添加到收藏夹

Editorial Material Clinical Neurology

Discrepancy in redetermination of SMN2 copy numbers in children with SMA

David Christof Schorling et al.

NEUROLOGY (2019)

添加到收藏夹

Article Health Care Sciences & Services

Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives

Tamara Dangouloff et al.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)

添加到收藏夹

Article Clinical Neurology

One Year of Newborn Screening for SMA - Results of a German Pilot Project

Katharina Vill et al.

JOURNAL OF NEUROMUSCULAR DISEASES (2019)

添加到收藏夹

Article Clinical Neurology

Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4

R. I. Wadman et al.

EUROPEAN JOURNAL OF NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care

Eugenio Mercuri et al.

NEUROMUSCULAR DISORDERS (2018)

添加到收藏夹

Article Medicine, General & Internal

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

E. Mercuri et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Pediatrics

Presymptomatic Diagnosis of Spinal Muscular Atrophy Through Newborn Screening

Yin-Hsiu Chien et al.

JOURNAL OF PEDIATRICS (2017)

添加到收藏夹

Article Clinical Neurology

218th ENMC International Workshop: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19-21 February 2016

Richard S. Finkel et al.

NEUROMUSCULAR DISORDERS (2017)

添加到收藏夹

Article Medicine, General & Internal

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

R. S. Finkel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Genetics & Heredity

Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy a literature review

Ingrid E. C. Verhaart et al.

ORPHANET JOURNAL OF RARE DISEASES (2017)

添加到收藏夹

Meeting Abstract Economics

THE UTILITY OF DIFFERENT APPROACHS TO DEVELOPING HEALTH UTILITIES DATA IN CHILDHOOD RARE DISEASES - A CASE STUDY IN SPINAL MUSCULAR ATROPHY (SMA)

R. Thompson et al.

VALUE IN HEALTH (2017)

添加到收藏夹

Article Clinical Neurology

Natural history of infantile-onset spinal muscular atrophy

Stephen J. Kolb et al.

ANNALS OF NEUROLOGY (2017)

添加到收藏夹

Article Clinical Neurology

Spinal Muscular Atrophy

Stephen J. Kolb et al.

NEUROLOGIC CLINICS (2015)

添加到收藏夹

Article Pediatrics

Survival of Patients With Spinal Muscular Atrophy Type 1

Cesare Gregoretti et al.

PEDIATRICS (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of > 72 400 specimens

Elaine A. Sugarman et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2012)

添加到收藏夹

Review Clinical Neurology

Spinal Muscular Atrophy A Timely Review

Stephen J. Kolb et al.

ARCHIVES OF NEUROLOGY (2011)

添加到收藏夹

Review Genetics & Heredity

Spinal muscular atrophy

Adele D'Amico et al.

ORPHANET JOURNAL OF RARE DISEASES (2011)

添加到收藏夹

Article Economics

Populating an Economic Model with Health State Utility Values: Moving toward Better Practice

Roberta Ara et al.

VALUE IN HEALTH (2010)

添加到收藏夹

Article Genetics & Heredity

Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene

Laura Alias et al.

HUMAN GENETICS (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

New insights on the evolution of the SMN1 and SMN2 region:: simulation and meta-analysis for allele and haplotype frequency calculations

S Ogino et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2004)

添加到收藏夹

Article Pediatrics

Spinal muscular atrophy: Survival pattern and functional status

BHY Chung et al.

PEDIATRICS (2004)

添加到收藏夹

Article Genetics & Heredity

Genetic risk assessment in carrier testing for spinal muscular atrophy

S Ogino et al.

AMERICAN JOURNAL OF MEDICAL GENETICS (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.